Whoever spread the virus had an agenda
By Ralph T Niemeyer
Whenever western free democracies and their capitalistic model are hit by a crisis, one can bet that in Eastern Asia there will be a pandemic crisis that will pose a threat for growth in that region.
Mainstream media is reporting massively about the so called coronavirus which has suddenly and without being known to anybody before spread just out of nowhere starting to affect millions with first deaths being reported, too.
But, closer scrutiny reveals that the coronavirus is anything but a surprise to modern science as numerous patents reaching almost 40 years back. And, the good news is at hand, too, but won’t be reported yet: there are remedies and vaccinations available.
The government of the People’s Republic of China reacted swiftly and professionally and took the right measurements to counter the attack by whoever has spread the virus.
Of course it is tragic that any person is being affected and that there are casualties, but in Germany in 2017 about 25,000 people fell victim of the grip virus, and every year in that season at least 10,000 people die from it, allover Europe more than 100,000.
Important is that vaccination and medical treatment is being provided at mass scale. To say that one doesn’t know about the virus and therefore there was no remedy to counter it is typical Fakenews by western media.
Another possibility is likely to be interlinked with the sudden outbreak in Wuhan which has been presented by the government of the People’s Republic as the first city to be entirely covered by the laser bundle standard of 5G. It would be remarkable that the virus is being used to attack the most advanced area of China.
It is also clear that the Coronavirus pandemonium would perfectly cover up the deep crisis the neo-liberal economic system is in once more after 2008, and it would potentially harm the US economy to an extent that it might cost President Trump his re-election – probably the only way for Democrats after their Impeachment disaster to prevent Mr Trump from winning by a landslide again.
Below the list of the most important patents in this regard:
CORONAVIRUS PROTEINS AND ANTIGEN publication number: 20160339097
Summary: Here, a method for collecting, extracting or eluting proteins and antigens from cells infected with the coronavirus is presented. The corona virus can be a porcine corona virus, e.g. the Porcine epidemic diarrhea virus (PEDV) or the porcine delta coronavirus (PDCoV).
Also disclosed are representations of a composition containing the proteins and antigens of the coronavirus, and representations of a method for using such a composition. Applications for the composition include, but are not limited to, use in the production of antibodies to the proteins and antigens, use as a reference marker for coronavirus proteins and / or use in an immunogenic composition such as e.g. in a vaccine composition.
Submitted: August 4, 2016 Release date: November 24, 2016 Applicant: MJ Biologics, Inc. Inventor: Byoung-Kwan Kim
CORONAVIRUS PROTEINS AND ANTIGEN publication number: 20190202868
Summary: The representation of a method for the collection, extraction or elution of proteins and antigens from cells infected with coronaviruses disclosed herein. The corona virus can be a porcine corona virus, e.g. the Porcine epidemic diarrhea virus (PEDV) or the porcine delta coronavirus (PDCoV).
Representations of a composition that contains the proteins and antigens of the coronavirus are also disclosed, as are representations of a method for using such a composition. Applications for the composition include, but are not limited to, use in the production of antibodies to the proteins and antigens, use as a reference marker for coronavirus proteins and / or use in an immunogenic composition such as e.g. in a vaccine composition.
Submitted: March 15, 2019 Publication date: July 4, 2019 Applicant: Inventor of Phibro Animal Health Corporation: Byoung-Kwan Kim
Coronavirus proteins and antigenic patent number: 10280199
Summary: The embodiments of a method for collecting, extracting, or eluting proteins and antigens from cells infected with coronavirus disclosed herein. The corona virus can be a porcine corona virus, e.g. the Porcine epidemic diarrhea virus (PEDV) or the porcine delta coronavirus (PDCoV). Also disclosed are representations of a composition containing the proteins and antigens of the coronavirus, and embodiments of a method for using such a composition. Applications for the composition include, but are not limited to, use in the production of antibodies to the proteins and antigens, use as a reference marker for coronavirus proteins and / or use in an immunogenic composition such as e.g. in a vaccine composition.
Filed August 4, 2016 Patent Date May 7, 2019 Assignee: Inventor: Phibro Animal Health Corporation: Byoung-Kwan Kim
Vaccine compositions and methods for the treatment of coronavirus infections. Publication number: 20060286124
Summary: The present publication relates to compositions and methods for the treatment or prevention of coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, a fragment, or a variant thereof, that are capable of eliciting a protective humoral and / or cell-mediated immune response, the compositions for treating or preventing Infections by corona viruses, such as the pathogen of SARS, are useful.
Coronavirus S-protein and N-protein immunogen compositions are also provided which contain an adjuvant, such as proteosome or protollin, which can be used to treat or prevent infection caused by a coronavirus, such as a SARS coronavirus.
Application Stored: June 30, 2005 Release Date: December 21, 2006 Applicant: ID Biomedical Corporation of Quebec Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones. The ID Biomedical Corporation of Quebec Inventors is funded by the Bill and Melinda Gates foundation.
Uncharacterized ORF3 in the SARS coronavirus is a cyclic AMP-dependent kinase and a target for SARS therapy publication number: 20050276818
Summary: The present invention relates to novel methods of identifying antiviral agents that selectively interfere with viral proteins that cause the unique infection activity of SARS coronavirus compared to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents that selectively inhibit cyclic AMP-dependent protein kinase activity of the SARS coronavirus ORF3. The present invention also relates to screening assays that identify drugs that selectively inhibit the interaction between the cyclic AMP-dependent protein kinase of SARS coronavirus and a calcium-dependent target molecule. Therefore, the agents identified using the assays of the invention can be useful as antiviral agents. The present invention also relates to the treatment of severe acute respiratory syndrome caused by coronary syndrome, and in particular to treatments that affect the infection activity of the SARS coronavirus.
Application filed: May 17, 2005 Release date: December 15, 2005 Inventors: Adam Godzik, Sergey Sikora
Uncharacterized ORF3 in the SARS coronavirus is a cyclic AMP-dependent kinase and a target for SARS therapy. Patent number: 7504205
Summary: The present invention relates to novel methods of identifying antiviral agents that selectively interfere with viral proteins that cause the unique infection activity of SARS coronavirus compared to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents that selectively inhibit cyclic AMP-dependent protein kinase activity of the SARS coronavirus ORF3. The present invention also relates to screening assays that identify drugs that selectively inhibit the interaction between the cyclic AMP-dependent protein kinase of SARS coronavirus and a calcium-dependent target molecule. Therefore, the agents identified using the assays of the invention can be useful as antiviral agents. The present invention also relates to treatments for severe acute respiratory syndrome caused by a coronavirus, and more particularly to treatments that affect the infection activity of the SARS coronavirus.
Filed May 17, 2005 Patent Date: March 17, 2009 Assignee: The Burnham Institute Inventors: Adam Godzik, Sergey Sikora
Inactivated Coronavirus Vaccine for Dogs Patent Number: 4567042
Summary: An effective, parenterally administered, inactivated coronavirus vaccine for dogs is produced which offers systemic, humoral protection and also protection of the intestinal tract of dogs from infection with the virulent coronavirus. A method of multiplying and attenuating the coronavirus and a method of evaluating the effectiveness of a coronavirus vaccine in dogs is also presented.
Filed June 7, 1984 Patent Date January 28, 1986 Assignee: Inventor of American Home Products Corporation: William M. Acree, Bobby Edwards, John W. Black
CANINE RESPIRATORY CORONAVIRUS (CRCV) MIRROR PROTEIN, POLYMERASE AND HEMAGGLUTINININ / ESTERASE Publication number: 20090081780
Summary: A dog respiratory coronavirus (CRCV) that occurs in the airways of dogs with a dog’s infectious respiratory disease and has low homology to enteric dog coronavirus, but has high homology to all bovine coronavirus strains (eg, Quebec and LY138) and the human coronavirus strain OC43. The Bill and Melinda Gates foundation is a founder.
Application filed: September 26, 2008 Publication date: March 26, 2009 Applicant: The inventors of the Royal Veterinary College: John Brownlie, Victoria Jane Chalker, Kerstin Erles
PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITATING SARS CORONAVIRES AND THE USE THEREOF Publication number: 20100304363
Summary: Peptide compounds and their use for the detection and inhibition of SARS coronaviruses are disclosed here. The compounds composed of dipeptides for the detection and inhibition of the SARS coronavirus can be easily synthesized and produced inexpensively. In addition, they can be safely stored over a long period of time. The dipeptide compounds are suitable both as inhibitors of the SARS coronavirus and as excellent capture materials for the SARS coronavirus.
Application filed: May 26, 2010 Date published: December 2, 2010 Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE Inventor: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo
Canine Respiratory Coronavirus (Crcv) spike protein, polymerase and hemagglutinin / esterase publication number: 20070248616
Summary: A dog respiratory coronavirus (CRCV) that occurs in the respiratory tract of dogs with a dog’s infectious respiratory disease and has low homology to the enteric coronavirus of the dog, but has a high homology to all strains of coronavirus in cattle (eg Quebec and LY138) and the human coronavirus strain OC43. The CRCV spike, the polymerase and the hemagglutinin / esterase cDNA as well as the partial protein sequences are shown in Figures (1) to (4), (13) and (14).
Application filed: July 1, 2003 Publication date: October 25, 2007 Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
Respiratory coronavirus (CRCV) spike protein in dogs. Patent Number: 7981427
Summary: A dog respiratory coronavirus (CRCV) that occurs in the airways of dogs with a dog’s infectious respiratory disease and has low homology to the enteric coronavirus in dogs, but high homology to all coronavirus strains in cattle (e.g. Quebec and LY138) and the human coronavirus strain OC43.
Filed September 26, 2008 Date Patent: July 19, 2011 Assignee: The inventors of the Royal Veterinary College: John Brownlie, Victoria Jane Ch
Grant submitted: September 26, 2008 Date of patent: July 19, 2011 Beneficiary: The inventors of the Royal Veterinary College: John Brownlie, Victoria Jane Chalker, Kerstin Erles
Methods and compositions for SARS coronavirus infectious cDNA publication number: 20060240530
Summary: The present invention provides a severe acute respiratory syndrome (SARS) corona virus cDNA, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and / or vaccines and / or expressing heterologous nucleic acids.
Application filed: January 19, 2006 Release date: October 26, 2006 Inventors: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis
Compositions and methods for detecting acute acute respiratory syndrome coronavirus publication number: 20050095582
Summary: The invention provides compositions and methods
